Is Zydus Lifesci. overvalued or undervalued?

As of May 20, 2025, Zydus Lifesciences is considered undervalued and attractive with a PE ratio of 20.61, outperforming peers like Sun Pharma and Divi's Lab, and demonstrating strong long-term growth despite recent underperformance against the Sensex.

As of 20 May 2025, the valuation grade for Zydus Lifesciences has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 20.61, an EV to EBITDA ratio of 13.04, and a PEG ratio of 0.92, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Zydus Lifesciences stands out as attractive against Sun Pharma, which is considered expensive with a PE ratio of 35.25, and Divi's Lab, which is very expensive at a PE ratio of 79.33. Additionally, Zydus has a higher ROCE of 31.73% compared to Cipla's 22.99%, reinforcing its strong operational efficiency. While the stock has underperformed the Sensex over the past year, it has shown significant gains over a three and five-year period, indicating a robust long-term growth trajectory.

Who are the top shareholders of the Zydus Lifesci.?

The top shareholders of Zydus Lifesci include the Zydus Family Trust with 74.96%, mutual funds at 6.36%, foreign institutional investors at 7.32%, and the Life Insurance Corporation of India at 3.85%, while individual investors hold about 5.41%.

The top shareholders of Zydus Lifesci include the Zydus Family Trust, which holds the highest stake at 74.96%. Other significant shareholders are mutual funds, which collectively hold 6.36%, and foreign institutional investors (FIIs), with a combined holding of 7.32%. The highest public shareholder is the Life Insurance Corporation of India, owning 3.85%. Additionally, individual investors hold about 5.41% of the company.

Who are in the management team of Zydus Lifesci.?

As of March 2022, the management team of Zydus Lifesci includes Chairman Pankaj R Patel, Managing Director Sharvil P Patel, and several independent directors, along with executive and compliance roles, ensuring effective governance and strategic direction.

As of March 2022, the management team of Zydus Lifesci includes the following individuals:<BR><BR>1. **Pankaj R Patel** - Chairman (Non-Executive)<BR>2. **Sharvil P Patel** - Managing Director<BR>3. **Mukesh M Patel** - Director<BR>4. **Nitin Raojibhai Desai** - Independent Director<BR>5. **Dharmishta N Rawal** - Independent Director<BR>6. **Apurva S Diwanji** - Independent Director<BR>7. **Ganesh N Nayak** - Executive Director<BR>8. **Bhadresh K Shah** - Independent Director<BR>9. **Dhaval N Soni** - Company Secretary & Compliance Officer<BR>10. **Akhil A. Monappa** - Independent Director<BR>11. **Upasana Konidela** - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

What is the bonus history of the Zydus Lifesci.?

Zydus Lifesciences Ltd has issued bonuses in the past, with the most recent being a 1:2 bonus on April 5, 2010, and a 1:1 bonus on August 30, 2006. These actions reflect the company's commitment to enhancing shareholder value.

Zydus Lifesciences Ltd has a history of issuing bonuses. The most recent bonus was a 1:2 bonus issue, which was announced with an ex-date of April 5, 2010, and the record date was April 6, 2010. Prior to that, the company issued a 1:1 bonus on August 30, 2006, with a record date of August 31, 2006. This indicates that Zydus Lifesciences has engaged in bonus issues to enhance shareholder value in the past.

Has Zydus Lifesci. declared dividend?

Yes, Zydus Lifesciences Ltd has declared a 300% dividend, amounting to ₹3 per share, with an ex-date of July 26, 2024. While recent short-term returns have been negative, the company has shown strong total returns over the longer term.

Zydus Lifesciences Ltd has declared a 300% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 300%<BR>- Amount per share: 3 per share<BR>- Ex-date: 26 Jul 24<BR><BR>Dividend Yield: 0.31%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -3.75%, the dividend return was 0%, resulting in a total return of -3.75%.<BR><BR>Over the past year, the price return was -8.24%, the dividend return was 0.28%, leading to a total return of -7.96%.<BR><BR>In the 2-year period, the price return was 85.73%, the dividend return was 1.62%, culminating in a total return of 87.35%.<BR><BR>For the 3-year period, the price return was 162.57%, the dividend return was 3.36%, resulting in a total return of 165.93%.<BR><BR>In the last 4 years, the price return was 50.47%, the dividend return was 2.34%, which led to a total return of 52.81%.<BR><BR>Over the past 5 years, the price return was 166.74%, the dividend return was 4.13%, resulting in a total return of 170.87%.<BR><BR>Overall, Zydus Lifesciences Ltd has declared a substantial dividend, which contributes positively to its long-term total returns, especially over the 2, 3, 4, and 5-year periods. However, the recent short-term returns indicate some volatility, with negative performance in the last year and six months.

Who are the peers of the Zydus Lifesci.?

Zydus Lifesci.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Lupin, Aurobindo Pharma, Abbott India, Alkem Lab, and GlaxoSmithKline Pharma. Zydus Lifesci. has good management risk and growth, but its 1-year return is -9.94%, the lowest among its peers.

Peers: The peers of Zydus Lifesci. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Lupin, Aurobindo Pharma, Abbott India, Alkem Lab, and Glaxosmi. Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, and the rest. Good management risk is found at Zydus Lifesci., Divi's Lab., Torrent Pharma, and Lupin. Average management risk is noted at Lupin. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Zydus Lifesci., and Lupin, while below average growth is seen at Divi's Lab., Torrent Pharma, Aurobindo Pharma, and Alkem Lab. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Zydus Lifesci., Aurobindo Pharma, Abbott India, and Alkem Lab, while good capital structure is found at Torrent Pharma and Lupin.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Zydus Lifesci. has the lowest at -9.94%. Zydus Lifesci.'s return is significantly lower than the highest peer. Additionally, the peers with negative six-month returns include Zydus Lifesci., Lupin, Aurobindo Pharma, and Alkem Lab.

What does Zydus Lifesci. do?

Zydus Lifesciences Ltd is a major Indian pharmaceutical and biotechnology company, formerly known as Cadila Healthcare, with recent net sales of ₹65,279 Cr and a net profit of ₹11,709 Cr for Q1 2025. It has a market cap of ₹97,363 Cr and key metrics include a P/E ratio of 21.00 and a dividend yield of 0.31%.

Overview:<BR>Zydus Lifesciences Ltd is a leading innovation-driven pharmaceutical company in India, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap entity.<BR><BR>History:<BR>Zydus Lifesciences Ltd was formerly known as Cadila Healthcare Limited. The company is currently reporting its financial results for the quarter ending March 2025, with net sales and profit figures available for this period.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 65,279 Cr (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: 11,709 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: INR 97,363 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.31%<BR>Debt-Equity: -0.19<BR>Return on Equity: 19.58%<BR>Price to Book: 4.06<BR><BR>Contact Details:<BR>Address: Zydus Corporate Park S No 536, Khoraj Sarkhej-Gandhinagar H/W Ahmedabad Gujarat : 382481<BR>Tel: 91-079-26868100<BR>Email: upen.shah@zyduscadila.com<BR>Website: http://www.zyduscadila.com

How big is Zydus Lifesci.?

As of 24th July, Zydus Lifesciences Ltd has a market capitalization of 97,006.00 Cr, with recent Net Sales of 23,241.50 Cr and a Net Profit of 4,525.50 Cr.

As of 24th July, Zydus Lifesciences Ltd has a market capitalization of 97,006.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, Zydus Lifesciences reported Net Sales of 23,241.50 Cr and a Net Profit of 4,525.50 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 23,953.10 Cr and Total Assets totaling 34,857.90 Cr.

When is the next results date for Zydus Lifesci.?

Zydus Lifesci. will announce its results on 06 November 2025.

Zydus Lifesci. is scheduled to declare its results on 06 November 2025.

Are Zydus Lifesci. latest results good or bad?

Zydus Lifesciences' latest results show strong year-on-year revenue growth of 16.92% and a 38.13% increase in net profit; however, there are concerns due to sequential declines in both revenue and profit, along with rising interest costs, leading to a downgrade in its Mojo Score from 'Buy' to 'Hold'.

Zydus Lifesciences' latest results present a mixed picture. On one hand, the company achieved a robust year-on-year revenue growth of 16.92%, with net sales reaching ₹6,123.20 crores. Additionally, net profit saw a significant increase of 38.13% year-on-year, totaling ₹1,258.60 crores. These figures indicate strong top-line growth and improved profitability compared to the previous year.<BR><BR>However, there are notable concerns. The sequential performance shows a decline, with net profit and revenue both decreasing by 14.19% and 6.85% respectively compared to the previous quarter. This decline raises questions about the company's operational efficiency and cost management in a competitive environment. Furthermore, the sharp rise in interest costs, which surged by 303.59% year-on-year to ₹101.30 crores, has significantly impacted the bottom line and reduced the company's interest coverage ratio.<BR><BR>Overall, while the year-on-year growth metrics are favorable, the sequential declines and rising costs have led to a downgrade in the company's Mojo Score from 'Buy' to 'Hold'. This suggests that while Zydus Lifesciences has strong fundamentals, it is currently facing challenges that warrant caution.

How has been the historical performance of Zydus Lifesci.?

Zydus Lifesci has shown consistent growth in net sales and profits, with net sales increasing from ₹14,253.10 Cr in March 2020 to ₹23,241.50 Cr in March 2025, and profit after tax rising from ₹1,175.60 Cr to ₹4,614.80 Cr during the same period, indicating strong financial performance and operational efficiency.

Answer:<BR>The historical performance of Zydus Lifesci shows a consistent growth trend in net sales and profits over the years, with significant increases noted in the latest fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Zydus Lifesci's net sales have risen from 14,253.10 Cr in March 2020 to 23,241.50 Cr in March 2025, reflecting a strong upward trajectory. The total operating income has followed a similar pattern, increasing from 14,253.10 Cr in March 2020 to 23,241.50 Cr in March 2025. The operating profit (PBDIT) has also improved significantly, growing from 2,897.30 Cr in March 2020 to 7,328.00 Cr in March 2025, indicating enhanced operational efficiency. Profit before tax has surged from 1,495.40 Cr in March 2020 to 6,026.70 Cr in March 2025, while profit after tax has increased from 1,175.60 Cr to 4,614.80 Cr during the same period. The earnings per share have more than tripled, rising from 11.49 in March 2020 to 44.99 in March 2025. On the balance sheet, total assets have grown from 22,833.70 Cr in March 2020 to 34,857.90 Cr in March 2025, while total liabilities have decreased from 7,901.10 Cr to 0.00 Cr, showcasing a strong financial position. Cash flow from operating activities has also improved, increasing from 2,931.00 Cr in March 2020 to 6,776.00 Cr in March 2025, contributing to a positive net cash inflow in the latest fiscal year. Overall, Zydus Lifesci has demonstrated robust growth across key financial metrics over the past several years.

Is Zydus Lifesci. technically bullish or bearish?

As of December 1, 2025, Zydus Lifesci. has shifted to a mildly bearish trend, indicated by bearish signals in the MACD and Bollinger Bands, despite some mildly bullish daily moving averages.

As of 1 December 2025, the technical trend for Zydus Lifesci. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by bearish signals in the MACD and Bollinger Bands on both weekly and monthly time frames. The KST also indicates a mildly bearish trend. The daily moving averages show a mildly bullish signal, but this is overshadowed by the overall bearish indicators. The RSI shows no signal, and Dow Theory indicates no trend in both weekly and monthly assessments. Overall, the strength of the bearish stance is supported by the prevailing trends across multiple indicators.

Should I buy, sell or hold Zydus Lifesci.?

Which are the latest news on Zydus Lifesci.?

Why is Zydus Lifesci. falling/rising?

As of 05-Dec, Zydus Lifesciences Ltd's stock price is 933.10, down 0.22% and has declined for three consecutive days. Despite strong long-term fundamentals, the stock is underperforming against benchmarks and trading below key moving averages, contributing to its recent bearish trend.

As of 05-Dec, Zydus Lifesciences Ltd's stock price is currently at 933.10, reflecting a decrease of 2.1 points or 0.22%. The stock has been experiencing a downward trend, having fallen for the last three consecutive days, resulting in a total decline of 0.99% during this period. This decline is further illustrated by the stock's performance over various time frames; it has decreased by 4.09% over the past month and 4.61% over the past year, while the benchmark Sensex has shown positive returns in those same periods.<BR><BR>The stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Additionally, despite a rise in investor participation, with delivery volume increasing by 25.3% against the 5-day average, the overall market sentiment appears to be negative, contributing to the stock's decline.<BR><BR>While the company has strong long-term fundamentals, such as low debt and healthy growth in net sales and operating profit, these factors have not been sufficient to counteract the recent price drop. The stock's performance relative to its peers and the broader market has also been underwhelming, with a year-to-date decline of 3.85% compared to a 9.69% increase in the Sensex. Thus, the combination of recent price movements, underperformance against benchmarks, and trading below key moving averages are key reasons for the stock's current decline.